Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ocugen expects funds to enable operations into 2Q23 » 07:34
08/05/22
08/05
07:34
08/05/22
07:34
OCGN

Ocugen

$2.75 /

+0.065 (+2.42%)

The Company's cash,…

The Company's cash, cash equivalents, and restricted cash totaled $115.0 million as of June 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into the second quarter of 2023. The Company had 216.1 million shares of common stock outstanding as of June 30, 2022.

ShowHide Related Items >><<
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

  • 23
    Feb
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

Earnings
Ocugen reports Q2 EPS (9c), consensus (8c) » 07:33
08/05/22
08/05
07:33
08/05/22
07:33
OCGN

Ocugen

$2.75 /

+0.065 (+2.42%)

"The second quarter…

"The second quarter was marked by several important milestones," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "On the vaccine front, we continued to work diligently with our co-development partner, Bharat Biotech, to ensure we execute our planned clinical and commercial objectives for COVAXIN - a whole-virion inactivated COVID-19 vaccine candidate. We are also excited and encouraged by the positive momentum of our investigational modifier gene therapy platform, with the potential to address many different gene mutations in the retina and look forward to bringing hope to patients for whom no treatment options exist. With our diversified portfolio, Ocugen is well-positioned to advance our product development efforts and we look forward to sharing key data as these programs progress."

ShowHide Related Items >><<
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

  • 23
    Feb
OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

OCGN Ocugen
$2.75 /

+0.065 (+2.42%)

Over a month ago
On The Fly
Meet Ocugen: Fly exclusive interview with CEO Shankar Musunuri » 13:10
06/30/22
06/30
13:10
06/30/22
13:10
OCGN

Ocugen

$2.34 /

+0.075 (+3.31%)

In an exclusive interview…

ShowHide Related Items >><<
OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

  • 23
    Feb
OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

OCGN Ocugen
$2.34 /

+0.075 (+3.31%)

Hot Stocks
Ocugen 'not just a COVAXIN company,' CEO tells The Fly  13:00
06/30/22
06/30
13:00
06/30/22
13:00
OCGN

Ocugen

$2.35 /

+0.08 (+3.53%)

 
ShowHide Related Items >><<
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

  • 23
    Feb
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

Hot Stocks
COVAXIN interim data by year-end 'would be good,' Ocugen CEO says  13:00
06/30/22
06/30
13:00
06/30/22
13:00
OCGN

Ocugen

$2.35 /

+0.08 (+3.53%)

 
ShowHide Related Items >><<
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

  • 23
    Feb
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

Hot Stocks
Ocugen CEO says NeoCart, OCU400 trials going 'as expected'  13:00
06/30/22
06/30
13:00
06/30/22
13:00
OCGN

Ocugen

$2.35 /

+0.08 (+3.53%)

 
ShowHide Related Items >><<
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

  • 23
    Feb
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

Hot Stocks
Ocugen expects COVAXIN BLA filing, approval by 2H23, CEO says  13:00
06/30/22
06/30
13:00
06/30/22
13:00
OCGN

Ocugen

$2.35 /

+0.08 (+3.53%)

 
ShowHide Related Items >><<
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

  • 23
    Feb
OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

OCGN Ocugen
$2.35 /

+0.08 (+3.53%)

Options
Unusually active option classes on open June 24th » 09:40
06/24/22
06/24
09:40
06/24/22
09:40
BHP

BHP Group

$54.75 /

-0.005 (-0.01%)

, VUZI

Vuzix

$7.16 /

+ (+0.00%)

, BHC

Bausch Health

$7.28 /

+ (+0.00%)

, OCGN

Ocugen

$2.54 /

+ (+0.00%)

, ZEN

Zendesk

$57.97 /

-0.05 (-0.09%)

, RBLX

Roblox

$34.48 /

+ (+0.00%)

, GS

Goldman Sachs

$286.35 /

+ (+0.00%)

, CHPT

ChargePoint

$15.55 /

+ (+0.00%)

, F

Ford

$11.56 /

+ (+0.00%)

, PLTR

Palantir

$9.45 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: BHP Billiton (BHP), Vuzix (VUZI), Bausch Health (BHC), Ocugen (OCGN), Zendesk (ZEN), Roblox (RBLX), Goldman Sachs (GS), ChargePoint Holdings (CHPT), Ford (F), and Palantir Technologies (PLTR).

ShowHide Related Items >><<
ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

VUZI Vuzix
$7.16 /

+ (+0.00%)

RBLX Roblox
$34.48 /

+ (+0.00%)

PLTR Palantir
$9.45 /

+ (+0.00%)

OCGN Ocugen
$2.54 /

+ (+0.00%)

GS Goldman Sachs
$286.35 /

+ (+0.00%)

F Ford
$11.56 /

+ (+0.00%)

CHPT ChargePoint
$15.55 /

+ (+0.00%)

BHP BHP Group
$54.75 /

-0.005 (-0.01%)

BHC Bausch Health
$7.28 /

+ (+0.00%)

BHP BHP Group
$54.75 /

-0.005 (-0.01%)

06/22/22 JPMorgan
BHP Group price target lowered to 2,590 GBp from 2,640 GBp at JPMorgan
06/07/22 Jefferies
BHP Group upgraded to Buy from Hold at Jefferies
06/01/22 Goldman Sachs
BHP Group reinstated with a Buy at Goldman Sachs
06/01/22 BMO Capital
BHP Group price target lowered to 3,000 GBp from 3,200 GBp at BMO Capital
VUZI Vuzix
$7.16 /

+ (+0.00%)

03/02/22 Craig-Hallum
Vuzix price target lowered to $11 from $30 at Craig-Hallum
12/21/21
Vuzix initiated with a Buy at Dawson James
BHC Bausch Health
$7.28 /

+ (+0.00%)

06/13/22 JPMorgan
Bausch Health resumed with an Overweight at JPMorgan
05/31/22 BofA
Bausch + Lomb initiated with a Buy at BofA
05/26/22 Piper Sandler
Bausch Health price target lowered to $7 from $27 at Piper Sandler
05/11/22 BMO Capital
Bausch Health price target lowered to $15 from $26 at BMO Capital
OCGN Ocugen
$2.54 /

+ (+0.00%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

06/17/22 Evercore ISI
Zendesk price target lowered to $66 from $128 at Evercore ISI
06/13/22 Morgan Stanley
Zendesk downgraded to Equal Weight on lack of catalysts at Morgan Stanley
06/13/22 Morgan Stanley
Zendesk downgraded to Equal Weight from Overweight at Morgan Stanley
06/10/22 Stifel
Zendesk price target lowered to $100 from $150 at Stifel
RBLX Roblox
$34.48 /

+ (+0.00%)

06/17/22 Truist
Roblox downgraded to Hold from Buy at Truist
06/16/22 MKM Partners
Roblox price target lowered to $28 from $30 at MKM Partners
06/16/22 Morgan Stanley
Roblox price target lowered to $25 from $27 at Morgan Stanley
06/15/22 Stifel
Roblox price target lowered to $40 from $45 at Stifel
GS Goldman Sachs
$286.35 /

+ (+0.00%)

05/03/22 Oppenheimer
Goldman Sachs price target lowered to $519 from $546 at Oppenheimer
04/18/22 Gordon Haskett
Block director exit notable due to 'overlap' language, says Gordon Haskett
04/18/22 BMO Capital
Goldman Sachs price target lowered to $486 from $488 at BMO Capital
04/05/22 Piper Sandler
Goldman Sachs price target lowered to $430 from $465 at Piper Sandler
CHPT ChargePoint
$15.55 /

+ (+0.00%)

06/22/22 Stifel
ChargePoint price target lowered to $26 from $32 at Stifel
06/17/22 B. Riley
ChargePoint initiated with Buy on 'dominant' market share at B. Riley
06/02/22 DA Davidson
ChargePoint price target lowered to $20 from $25 at DA Davidson
06/01/22 Evercore ISI
ChargePoint price target lowered to $24 from $28 at Evercore ISI
F Ford
$11.56 /

+ (+0.00%)

06/01/22 Goldman Sachs
Ford price target lowered to $14 from $18 at Goldman Sachs
06/01/22 Citi
Citi lowers Ford tagret but opens '90-Day Upside Catalyst Watch'
05/20/22 Tigress Financial
Ford price target raised to $22 from $20 at Tigress Financial
05/13/22 Morgan Stanley
Ford upgraded to Equal Weight at Morgan Stanley following selloff
PLTR Palantir
$9.45 /

+ (+0.00%)

06/23/22 Goldman Sachs
Palantir initiated with a Neutral at Goldman Sachs
06/21/22 BofA
Palantir initiated with a Buy at BofA
05/10/22 Deutsche Bank
Palantir price target lowered to $11 from $15 at Deutsche Bank
05/10/22 Citi
Palantir price target lowered to $7 from $10 at Citi
ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

VUZI Vuzix
$7.16 /

+ (+0.00%)

RBLX Roblox
$34.48 /

+ (+0.00%)

PLTR Palantir
$9.45 /

+ (+0.00%)

OCGN Ocugen
$2.54 /

+ (+0.00%)

GS Goldman Sachs
$286.35 /

+ (+0.00%)

F Ford
$11.56 /

+ (+0.00%)

CHPT ChargePoint
$15.55 /

+ (+0.00%)

BHC Bausch Health
$7.28 /

+ (+0.00%)

  • 23
    Feb
  • 15
    Jul
ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

RBLX Roblox
$34.48 /

+ (+0.00%)

PLTR Palantir
$9.45 /

+ (+0.00%)

OCGN Ocugen
$2.54 /

+ (+0.00%)

GS Goldman Sachs
$286.35 /

+ (+0.00%)

F Ford
$11.56 /

+ (+0.00%)

BHP BHP Group
$54.75 /

-0.005 (-0.01%)

BHC Bausch Health
$7.28 /

+ (+0.00%)

ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

VUZI Vuzix
$7.16 /

+ (+0.00%)

RBLX Roblox
$34.48 /

+ (+0.00%)

PLTR Palantir
$9.45 /

+ (+0.00%)

OCGN Ocugen
$2.54 /

+ (+0.00%)

GS Goldman Sachs
$286.35 /

+ (+0.00%)

F Ford
$11.56 /

+ (+0.00%)

CHPT ChargePoint
$15.55 /

+ (+0.00%)

BHP BHP Group
$54.75 /

-0.005 (-0.01%)

BHC Bausch Health
$7.28 /

+ (+0.00%)

ZEN Zendesk
$57.97 /

-0.05 (-0.09%)

VUZI Vuzix
$7.16 /

+ (+0.00%)

RBLX Roblox
$34.48 /

+ (+0.00%)

PLTR Palantir
$9.45 /

+ (+0.00%)

OCGN Ocugen
$2.54 /

+ (+0.00%)

GS Goldman Sachs
$286.35 /

+ (+0.00%)

F Ford
$11.56 /

+ (+0.00%)

CHPT ChargePoint
$15.55 /

+ (+0.00%)

BHP BHP Group
$54.75 /

-0.005 (-0.01%)

BHC Bausch Health
$7.28 /

+ (+0.00%)

Hot Stocks
Ocugen announces publication of results of COVID-19 trial for children 2-18 » 07:04
06/21/22
06/21
07:04
06/21/22
07:04
OCGN

Ocugen

$2.16 /

+0.175 (+8.84%)

Ocugen announced the…

Ocugen announced the publication of positive pediatric Phase 2/3 study results in children aged 2-18 years for the COVID-19 vaccine COVAXIN in The Lancet Infectious Diseases. COVAXIN is developed and manufactured by Ocugen's partner Bharat Biotech International, a global leader in vaccine innovation based in Hyderabad, India, and is under clinical investigation by Ocugen in the United States for use in adults aged 18 years and older. The Lancet article, entitled "Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study," which was authored by Dr. Krishna Mohan Vadrevu, Siddharth Reddy, MSc, and others, was published on June 16, 2022. This data demonstrates that the same dose is effective in both pediatrics and adults and would be an ideal option as the majority of Americans are looking for traditional vaccine options. Ocugen is continuing its effort to bring this vaccine to the North American Market. The low reactogenicity might make COVAXIN more acceptable in pediatric populations than the more reactogenic mRNA vaccines as Bharat Biotech's pediatric Phase 2/3 study had no serious adverse events, deaths, or withdrawals due to an adverse event including no cases of Guillain-Barre syndrome, thromboembolic events, myocarditis, or pericarditis, or other adverse events of special interest being observed to date. Follow-up studies to assess pediatric effectiveness are underway, but this study suggests that similar efficacy, measured by the ability of a vaccine to prevent disease, might be anticipated in children based on the observation of superior immunogenicity, measured by the ability of a vaccine to produce an immune response, as compared to adults

ShowHide Related Items >><<
OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

  • 23
    Feb
OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

OCGN Ocugen
$2.16 /

+0.175 (+8.84%)

Upgrade
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential » 09:39
06/15/22
06/15
09:39
06/15/22
09:39
OCGN

Ocugen

$1.94 /

-0.04 (-2.03%)

Roth Capital analyst…

Roth Capital analyst Jonathan Aschoff resumed coverage of Ocugen at Buy, up from Neutral previously, with an $8 price target. He sees initial results from the Phase 1/2 trial with OCU400 in retinitis pigmentosa and Phase 2/3 COVAXIN results in the U.S. driving value, adding that the company has "a rich preclinical pipeline" behind those opportunities. Ocugen also has a "Phase 3-ready" program called NeoCart to repair full-thickness lesions of adult knee cartilage and ultimately prevent osteoarthritis, added Aschoff.

ShowHide Related Items >><<
OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
06/02/22 Cantor Fitzgerald
Ocugen initiated with an Overweight at Cantor Fitzgerald
05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
04/18/22 Roth Capital
Roth views Ocugen getting rights in Mexico as 'great news'
OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

  • 23
    Feb
OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

OCGN Ocugen
$1.94 /

-0.04 (-2.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.